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T
he pathologist makes do with 
red wine until an effective drug 
is available, the biochemist 
discards the bread from her 
sandwiches, and the mathematician 
indulges in designer chocolate with a 
clear conscience. The demographer 
sticks to vitamin supplements, and 
while the evolutionary biologist 
calculates the compensations of 
celibacy, the population biologist 
transplants gonads, but so far only 
those of his laboratory mice. Their 
common cause is to control and extend 
the healthy lifespan of humans. They 
want to cure ageing and the diseases 
that come with it.
“I would take resveratrol if it 
were feasible,” notes David Sinclair, 
assistant professor of pathology at 
Harvard Medical School in Boston, 
Massachusetts. In the meantime, he 
adds, “I do enjoy a glass of red wine 
about once a day.” It was Sinclair’s 
laboratory, in association with a 
commercial partner, that revealed last 
August how the team had identiﬁ  ed 
for the ﬁ  rst time a group of simple 
organic molecules capable of extending 
lifespan. The most proﬁ  cient of 
the group is resveratrol, the plant 
polyphenol found in red wine, and its 
discovery as a potential elixir to combat 
ageing represents another extraordinary 
advance in a decade of discoveries that 
have revolutionised the ﬁ  eld.
Extending Life
Although the life-enhancing 
effects of Sinclair’s polyphenols are 
so far conﬁ  ned to the baker’s yeast 
Saccharomyces cerevisiae, the work 
suggests that researchers are only one 
small step from making a giant leap 
for humankind. “People imagined that 
it might have been possible, but few 
people thought that it was going to be 
possible so quickly to ﬁ  nd such things,” 
says Sinclair. The ﬁ  eld of ageing 
research is buzzing.
Resveratrol stimulated a known 
activator of increased longevity in yeast, 
the enzyme Sir-2, and thereby extended 
the organism’s lifespan by 70% (Box 
1). Sir-2 belongs to a family of proteins 
with members in higher organisms, 
including SIR-2.1, an enzyme that 
regulates lifespan in worms, and SIRT-
1, the human enzyme that promotes 
cell survival (Figure 1). Though 
researchers still do not know whether 
SIRT-1, or “Sir-2 in humans,” as 
Sinclair puts it, has anything to do with 
longevity, there is a good chance that 
it does, judging by its pedigree. In any 
event, resveratrol proved to be a potent 
activator of the human enzyme. This 
might not be altogether surprising, 
at least not now, given that the 
polyphenol is already associated with 
health beneﬁ  ts in humans, notably the 
mitigation of such age-related defects 
as neurodegeneration, carcinogenesis, 
and atherosclerosis.
“The study came out from a pretty 
big gamble,” recalls Sinclair, who used 
the human enzyme to screen and 
identify molecules that he expected 
would also stimulate those related 
enzymes in lower organisms. Unlike 
SIRT-1, these related enzymes are 
known to increase longevity when 
activated, usually by restricting the 
organism’s calorie intake. Not only did 
they ﬁ  nd “a whole collection of related 
polyphenols that activate ‘Sir-2 from 
humans,’ … but we put them onto 
yeast, justbeing the simplest model, 
and amazingly [they] did what we 
were hoping [they] would do,” recalls 
Sinclair. “But it was a real long shot.”
Now there’s great eagerness in the 
Sinclair laboratory to complete and 
publish related research, notably by 
replicating the yeast work in higher 
organisms. “We have very promising 
results in Drosophila, which is a huge 
jump from a yeast cell,” says Sinclair. 
“So we’re very encouraged by 
that.” Publication of these results is 
imminent. The team has also quickly 
broadened its horizons and is already 
testing the polyphenols on mouse 
disease models. “We think we may 
have tapped into a cell survival and 
defence programme [and] that these 
molecules will be useful for treating 
diseases associated with ageing, like 
diabetes and Alzheimer’s,” says Sinclair. 
He hopes to publish the diabetes 
results by mid-2004 and those for 
Alzheimer’s by the end of the year. 
Harvard and BIOMOL Research 
Laboratories, its commercial partner 
based in Pennsylvania, have already 
ﬁ  led a patent application for the use of 
“synthetic related molecules” to combat 
diseases of ageing—an application, 
Sinclair adds, “very much linked to the 
[polyphenols] paper.”
There’s been a radical shift in 
attitude towards ageing, says Sinclair. 
Before the 1990s, “people thought that 
we were a lot like cars, that we would 
just rust and breakdown—nothing we 
could do about it. The new idea is that 
there are pathways that can boost our 
defences against ageing—the ‘ageing-
can-be-regulated’ discovery … that 
genes can control ageing [and] that 
there are pathways that [we can use 
to] slow down the process,” he says. “If 
that’s true—and it really seems to be 
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Figure 1. SIRT-1 Deacetylase—the Human 
Enzyme That Promotes Cell Survival—in a 
Dividing Human Cell
The enzyme is marked in red, and 
the image is superimposed on acetylated 
proteins (green) and condensed 
chromosomes (blue). (Image courtesy of 
David Sinclair.)January 2004  |  Volume 2  |  Issue 1  |  Page 0015 PLoS Biology  |  http://biology.plosjournals.org
true for a lot of organisms—if it’s true 
for us, it really means that there is hope 
that we will be able, one day, to ﬁ  nd 
small molecules that can alter these 
pathways.”
How Long Could We Live?
Sinclair expects to see such 
developments within his lifetime, but 
he ridicules the notion that humans 
will experience anything like the 70% 
extension to lifespan of his cultured 
yeast. “It’ll be great if we can just give 
people an extra ﬁ  ve years and have less 
disease in their old age and make it less 
painful,” he says. “We won’t be seeing 
any Methuselahs around,” he insists. 
On his side are James Vaupel, one of 
Europe’s leading demographers, and 
Marc Mangel, a mathematical modeller 
at the University of California at Santa 
Cruz. “Since 1840, life expectancy 
has been going up at 2.5 years per 
decade and will continue at this rate, 
maybe a little faster,” says Vaupel, 
head of the Laboratory of Survival 
and Longevity at the Max Planck 
Institute for Demographic Research in 
Rostock, Germany. Women in Japan 
currently have the highest average life 
expectancy of 85, he notes: “So the 
ﬁ  gure could be 100 in six decades, 
but not 500.” There’s remarkably little 
people can do even if they want to 
live as long as possible, he says. “Give 
up smoking, lose weight, don’t drive 
when drunk, install a smoke detector, 
take regular exercise,” suggests Vaupel, 
who insists he does them all, as well as 
taking vitamin supplements.
Mangel sees the problem of assessing 
the limitations of ageing research as 
fairly straightforward. Mathematical 
models, he says, could solve it by 
linking demographic properties and 
physiological developments. “We’ve had 
a separation of the biology of ageing 
and the demography of ageing, and they 
need to come together again,” notes 
Mangel, whose personal anti-ageing 
regime involves taking “a dose of anti-
oxidant chocolate with a good feeling.”
But Cythnia Kenyon, whose 
laboratory reported in October that 
it had generated a 6-fold increase in 
the lifespan of its nematodes, is not so 
sure about the limitations. “You look 
at these worms and think, ‘Oh my 
God, these worms should be dead.’ 
But they’re not. They’re moving 
around…. Once you get your brain 
wrapped around that … then you start 
thinking, oh my goodness, so lifespan 
is something you can change—it’s 
plastic. Then who knows what the limit 
is?” (Cynthia Kenyon has recorded 
video clips of the superstars of her lab, 
Caenorhabditis elegans, to show how long-
lived mutant nematodes are as vigorous 
as normal young adults [Videos 1-4].)
Warming to the theme, Kenyon 
hypothesises: “If you’d asked me many 
generations ago, when we were actually 
“You look at these worms 
and think, ‘Oh my God, these 
worms should be dead.’ But 
they’re not. They’re moving 
around.”
DOI: 10.1371/journal.pbio.0020012.v001
Video 1. Normal Nematodes at Day 1 of 
Adulthood
(Video used by permission from Cynthia 
Kenyon.)
Box 1. Model Systems for Ageing
Yeast, as a model system for ageing, is at a distinct disadvantage. It lacks an endocrine 
system, and yet much research indicates that the key to longevity is control of hormones such 
as insulin and insulin-like growth factor 1 (IGF-1), as well as their downstream pathways and 
associated tissues, including the reproductive network.
But David Sinclair, whose laboratory used yeast to show how an elixir might extend life, 
remains sanguine. “If it doesn’t have an endocrine system, we can’t understand cell-to-cell 
communication, but not all of ageing is just communication,” he says. “There are things that 
occur inside the cells that provide longevity, and that’s where yeast can be applied.”
Sinclair, assistant professor of pathology at Harvard Medical School, discovered a group of 
polyphenols that cause the human enzyme SIRT-1 and its homologues in lower organisms, 
including Sir-2 in yeast, to deacetylate the p53 protein and its homologues, notably the 
histones H3 and H4, in yeast.
“Our ﬁ  ndings are that the activation of the pathway downregulates p53’s ability to cause 
cell death,” he notes. Although p53, the tumour suppressor, is known to be involved in 
programmed cell death, it is not known whether SIRT-1 has any role in ageing. So Sinclair 
“went straight back to yeast to prove the principle of longevity extension.”
He found that deacetylisation of histones in yeast caused the DNA that’s wrapped around 
them to become more compact and thus more stable. “DNA stability is key to longevity, and 
Sir-2 promotes that,” says Sinclair. “We don’t know yet whether it’s the same in humans.”
Cynthia Kenyon, meanwhile, sees worms as the optimal model for helping to substantiate 
the links to humans. Besides the nematodes’ being multicellular organisms with endocrine 
systems, she also notes that their short lifespan of around 20 days is a big advantage: “You can 
do lots of experiments with them.” Mice, which have short lifespans for mammals, still live two 
years, and long-lived mice for three or four years, she notes. And the advantage of fruit ﬂ  ies? 
“It’s good to use more than one animal.”
Kenyon, professor of biochemistry and biophysics at the University of California at San 
Francisco, has focused on decoding the role of genes in ageing, notably daf-2, whose receptor 
is similar to those for insulin and IGF-1 in humans and inhibits ageing, and daf-16, which 
promotes it.
“The DAF-2 receptor activates a highly conserved PI-3-kinase, the PDK/Akt pathway, 
and that pathway affects ageing, at least in part, by inhibiting the activity of the DAF-16 
transcription factor,” says Kenyon. “It does so by phosphorylating DAF-16 and inhibiting its 
entry into the nucleus.” She adds: “We think that the DAF-2 pathway has another way of 
inﬂ  uencing ageing … but we don’t know what this other way is.”
In the long-lived mutants, which are defective in the daf-2 receptor gene or in the genes 
encoding downstream signalling components, such as the PI-3-kinase, DAF-16’s activity in the 
nucleus leads to the changes in expression of a wide variety of downstream genes, between 
100 and 200, estimates Kenyon. Her studies show, she says, that a large number of those genes 
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common precursors of worms and ﬂ  ies, 
‘Cynthia, you have a two-week lifespan, 
do you think that you could [live 
longer]?’ And if I’d told you, ‘Well, I 
think our descendants will live 1,000 
times longer,’ you’d have said, ‘Oh, 
come on!’ But we do. It happened,” she 
notes.
“Who knows what you could do in 
people?” Kenyon muses. “I don’t want 
to go on record saying that it’s not 
possible in people because I don’t see 
why it wouldn’t be…. I’m certainly not 
imagining that my company in the next 
few years is going to come up with a 
compound that can make people live to 
be 500. That seems just preposterous.” 
So the timescale is millions of years? 
“No, not necessarily,” she insists, 
“because once we understand the 
mechanism, then we can intervene and 
see what we can accomplish.”
Signalling Life and Sweet 16
Kenyon, professor of biochemistry 
and biophysics at the University of 
California at San Francisco, is among 
the key contributors responsible 
for showing that a single gene, and 
subsequently many genes, can change 
an organism’s lifespan.
In a seminal paper published a 
decade ago, Kenyon’s laboratory 
showed that mutations in the daf-2 gene 
doubled the lifespan of the nematode 
C. elegans. daf-2 encodes a receptor 
that is similar to those for insulin and 
insulin-like growth factor-1 (IGF-1) 
in humans; this hormone receptor 
normally speeds up ageing in worms, 
but the mutations inhibit its action and 
enable the organisms to live longer. 
Before the results appeared, there was a 
“very negative attitude” towards ageing 
research, recalls Kenyon. Since then, 
and especially over the past few years 
in response to later ﬁ  ndings, graduate 
students have been scrambling for a 
chance to work in her laboratory. “You 
can’t believe the difference—there was 
such resistance to it,” she says. “daf-2 
made a huge difference.” But then so 
did her subsequent research in the 
ﬁ  eld.
Among her most signiﬁ  cant ﬁ  ndings 
is the identiﬁ  cation of many more 
longevity genes; the results, published 
in July, derive directly from her early 
work on daf-2. “We discovered that in 
order for long-lived worms to live so 
long, they need another gene called 
daf-16,” recalls Kenyon. “daf-16 is 
kind of the opposite of daf-2, in the 
sense that it promotes longevity and 
youthfulness … so we call it ‘sweet 16.’” 
daf-16 encodes a transcription factor 
that controls the expression of more 
than 100 genes. “They don’t do just 
one thing, they do many things,” says 
Kenyon. They can act as anti-oxidants 
(to prevent damage from oxygen 
radicals), as chaperones (to prevent 
misfolded proteins from forming 
aggregates), as antimicrobials (to 
protect against bacteria and fungi), and 
as metabolic agents.
“So the picture that emerges is that 
the way the insulin/IGF-1 hormone 
system produces these enormous 
effects on lifespan is by coordinating 
the expression of many genes that do 
different things to affect lifespan, each 
of which on its own has only a small 
effect,” notes Kenyon. “It’s as though 
daf-2 and daf-16, the regulators, would 
be the conductors of an orchestra. 
They bring together the ﬂ  utes and 
the violins and the French horns, 
each of which do different things, and 
they make them all work together in 
concert.”
Kenyon is unequivocal about the 
bottom line: “Now we have a whole set 
of genes whose biochemical functions 
we can be working on to understand 
more about the actual mechanisms 
of ageing.” Complementary results in 
ﬂ  ies and mammals persuade her to be 
more explicit. “The common ancestor 
of worms, ﬂ  ies, and mice must have 
had an insulin/IGF-1-like hormone 
system that controlled ageing. And 
that ability has been maintained. So 
the question is, has [that ability] been 
lost in humans? I think it’s quite likely 
that it will also function in humans, but 
there isn’t a direct demonstration yet 
that that’s the case.”
Nevertheless, the discoveries about 
the role of the insulin/IGF-1 pathway 
in ageing have had a profound impact 
on her own lifestyle, which includes 
a tendency to discard the bread from 
sandwiches and eat only the toppings 
of pizzas (Box 2). “I’m on a low-carb 
diet. I gave my worms glucose, and it 
shortened their lifespan. [The diet] 
makes sense because it keeps your 
insulin levels down,” she says.
“Caloric restriction extends lifespan 
of mice, and so does the insulin/IGF-1 
pathway,” she notes. Indeed, starting 
a low-calorie diet at any point in 
adulthood appears to help fruit ﬂ  ies 
live longer, according to research 
in Britain published last September. 
“What we don’t know for sure in mice,” 
Kenyon continues, “is whether the two 
pathways are different or the same.”
While much ageing research focuses 
on these two inﬂ  uences, she says 
that there are another two areas of 
“It is inconceivable … that 
a life-extending therapy 
will ever be developed 
that is able to extend life 
independent of every other 
change.”
DOI: 10.1371/journal.pbio.0020012.v002
Video 2. Long-Lived daf-2 Mutants at Day 1 of 
Adulthood
(Video used by permission from Cynthia 
Kenyon.)
DOI: 10.1371/journal.pbio.0020012.v003
Video 3. Normal Nematodes at Day 13 of 
Adulthood
The worm on the left is dead. (Video used 
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investigation. Her laboratory reported 
in December 2002 that inhibiting 
the respiration of mitochondria in 
developing worms increased longevity, 
but that it had no effect in adult worms, 
for reasons still unexplained, she says. 
Further microarray analysis is underway 
to pinpoint whether the cause simply 
lies downstream of the insulin/IGF-1 
pathway or whether it is something 
different altogether.
 The Price of Life
Then there’s research looking at 
the effects on lifespan of changes to 
an organism’s reproductive system. 
For Kenyon, such work often involves 
a battle to convince sceptics that 
longevity is not a trade-off with fertility. 
Four years ago, her laboratory reported 
that killing germ cells increases 
the lifespan of worms by 60%, but 
only because, she stresses, it affects 
endocrine signalling and not because 
it prevents reproduction. Further 
research, published last year, showed 
quite clearly, she says, that ageing 
and reproduction are controlled 
independently of one another. And 
as for her recent work on infertile 
worms, which lived six times as long as 
normal following the removal of their 
entire reproductive systems, she says: 
“If we could intervene in the hormone 
signalling pathways directly, we think 
the animals would still live six times as 
long as normal, but would be fertile as 
well.”
Jim Carey is one of those “trade-off” 
sceptics. He is a population biologist 
at the University of California at Davis 
and his research, on the effect on life 
expectancy of replacing the ovaries of 
old mice with ovaries from younger 
mice, is intended to complement 
Kenyon’s work. But he insists that “an 
honest discussion of lifespan extension 
must include consideration of trade-
offs.” Many manipulations that extend 
lifespan in model systems, whether 
genetic or dietary, for example, ignore 
or gloss over the side effects, such 
as permanent sterility, huge weight 
loss, distorted organ-to-body ratios, 
or major behavioural aberrations, he 
notes. “It is inconceivable to me that 
a life-extending therapy will ever be 
developed that is able to extend life 
independent of every other change,” 
he concludes. “All life systems 
are interlinked and hierarchically 
integrated at all levels, so to talk about 
life extension using analogies with a car 
warranty concept is wrong-headed.”
Another “trade-off” sceptic takes 
a different tack. As Armand Leroi 
puts it: “During occasional periods of 
involuntary celibacy I have thought, 
well, I may not be getting laid, but 
at least I shall live to a miserable and 
solitary old age.” Leroi, an evolutionary 
biologist at Imperial College of Science, 
Technology, and Medicine in London, 
offers an optimistic appraisal of the 
chances of ﬁ  nding a cure for ageing 
in his new book about the effects of 
genetic variety on the human body. He 
sees ageing simply as a collection of 
curable diseases: “There is no obvious 
impediment to that advance, nothing 
to make us think that human beings 
have a ﬁ  xed lifespan.”  
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Box 2. Practise What You Preach
Cynthia Kenyon’s eating habits are deﬁ  ned by her ageing research on worms. “There’s a lot 
of these diets … and what they all have in common is low carb—actually, low glycaemic index 
carbs,” she says. “That’s not eating the kind of carbohydrates where the sugar gets into your 
bloodstream very quickly [and stimulates production of insulin].”
No desserts. No sweets. No potatoes. No rice. No bread. No pasta. “When I say ‘no,’ I mean 
‘no, or not much,’” she notes. “Instead, eat green vegetables. Eat the fruits that aren’t the sweet 
fruits, like melon.” Bananas? “Bananas are a little sweet.” Meat? “Meat, yes, of course. Avocados. 
All vegetables. Nuts. Fish. Chicken. That’s what I eat. Cheese. Eggs. And one glass of red wine a 
day.”
Kenyon, professor of biochemistry and biophysics at the University of California at San 
Francisco, has been on her diet for two-and-a-half years. “I did it because we fed our worms 
glucose and it shortened their lifespan.”
But the diet is unproven, she cautions, and she’s not recommending it for all. Nevertheless, 
she’s pleased with its performance for her. “I have a fabulous blood proﬁ  le. My triglyceride 
level is only 30, and anything below 200 is good.”
Kenyon is angered by the general lack of nutritional knowledge: “It’s a little bit 
embarrassing to say that scientists actually don’t know what you should eat…. We can target 
particular oncogenes, but we don’t know what you should eat. Crazy,” she says.
Does her dieting represent a return to scientists experimenting on themselves? “I don’t 
think so—you have to eat something, and you just have to make your best judgement. And 
that’s my best judgement. Plus, I feel better. Plus, I’m thin—I weigh what I weighed when I was 
in college. I feel great —you feel like you’re a kid again. It’s amazing.” 
DOI: 10.1371/journal.pbio.0020012.v004
Video 4. A Long-Lived daf-2 Mutant at Day 13 
of Adulthood
(Video used by permission from Cynthia 
Kenyon.)